%0 Journal Article
%T Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes.
%A Raniga K
%A Nasir A
%A Vo NTN
%A Vaidyanathan R
%A Dickerson S
%A Hilcove S
%A Mosqueira D
%A Mirams GR
%A Clements P
%A Hicks R
%A Pointon A
%A Stebbeds W
%A Francis J
%A Denning C
%J Cell Stem Cell
%V 31
%N 3
%D 2024 03 7
%M 38366587
%F 25.269
%R 10.1016/j.stem.2024.01.007
%X Advances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the large-scale production of hiPSC-CMs, implementation of hiPSC-CMs in industry settings, and recent clinical applications of this technology. The key observations are a need for traceable gender and ethnically diverse hiPSC lines, approaches to reduce cost of scale-up, accessible clinical trial datasets, and transparent guidelines surrounding the safety and efficacy of hiPSC-based therapies.